Lancet Publication Validates 8.2 vs 4.5-Month PFS Benefit for Savolitinib–Osimertinib
HUTCHMED’s SACHI Phase III trial, published in The Lancet, showed savolitinib plus osimertinib extended median investigator-assessed PFS to 8.2 months versus 4.5 months with chemotherapy in EGFR-mutated, MET-amplified NSCLC (HR 0.34; p<0.0001). The all-oral combination received China approval in June 2025.
1. Clarification of HCM Agreement
On January 15, 2026, Homeland Uranium Corp. confirmed that it entered into an investor relations services agreement with HoldCo Markets Advisory Inc. (HCM) on January 24, 2025. Under this one-year agreement, HCM, a Canadian firm specializing in research and coverage for junior/mid-cap metals and mining companies, committed to deliver research reports, peer analysis, information distribution and social media services to Homeland from January 24, 2025 through January 24, 2026. The clarification was made at the request of the TSX Venture Exchange, which noted that the original agreement had not been submitted for prior exchange approval.
2. Fee Structure and Payments
Homeland agreed to pay HCM a total cash fee of $33,600 plus applicable taxes for the Services. Payments were structured in four equal quarterly installments of $8,400 each, the first of which was due on the agreement’s effective date. All installments were remitted on schedule, reflecting a disciplined approach to managing investor relations expenditures within the Company’s corporate budget for 2025.
3. Early Termination Details
The Company exercised its right to terminate the HCM Agreement on September 18, 2025, more than four months before the scheduled end of the term. Upon termination, Homeland paid the remaining balance of the final quarterly installment in full on the termination date. Management has indicated there is no current intention to re-engage HCM or to enter into similar services agreements without prior exchange approval, underscoring a renewed compliance focus.
4. HCM Principal’s Equity Interests
HCM did not receive any securities from Homeland as compensation for its services. However, the sole principal of HCM holds 166,667 common shares of Homeland and 83,333 exercise warrants, each warrant exercisable at $0.50 per share until March 7, 2027. These holdings were acquired through participation in a private placement of subscription receipts on December 24, 2024, linked to a reverse take-over transaction that closed on March 7, 2025. To the Company’s knowledge, neither HCM nor its principal holds additional equity or equity-linked interests in Homeland.